<p>Sagimet Biosciences Inc.（納斯達克股票代碼：SGMT - 獲取免費報告）在 7 月份看到了空頭頭寸顯著下降。截至 7 月 15 日，空頭頭寸總計 1,670,000 股，較 6 月 30 日的 2,280,000 股減少了 26.8%。目前，該股的 8.0% 股份被空頭賣空。基於平均每日交易量為 536,900 股，目前的空頭頭寸比率為 3.1 天。</p>
<p>獲取 <strong>Sagimet Biosciences</strong> 警報：</p>
<h2>Sagimet Biosciences 股票表現</h2>
<p>納斯達克股票代碼：SGMT 週五午盤交易中上漲$0.02，達到$3.42。該股交易量為 239,160 股，低於其平均交易量 542,058 股。該公司的 50 天移動平均價格為$4.04，200 天移動平均價格為$5.52。Sagimet Biosciences 過去 12 個月的最低價為$2.13，最高價為$20.71。</p>
<p>Sagimet Biosciences（納斯達克股票代碼：SGMT - 獲取免費報告）上次公佈季度財報是在 5 月 15 日星期三。公司報告該季度每股虧損 ($0.23)，超過了每股 ($0.41) 的共識預期$0.18。股票研究分析師預計，Sagimet Biosciences 今年將實現-1.76 美元的每股盈利。</p>
<h2>內部人員的買賣行為</h2>
<p>據相關消息，董事長 George Kemble 於 7 月 19 日星期五以每股$3.10 的均價出售了公司 14,062 股股票。此次交易總價值為$43,592.20。交易完成後，董事長在公司擁有 142,318 股股份，價值$441,185.80。該交易已在提交給證券交易委員會的文件中披露，可通過 SEC 網站訪問。另外，Sagimet Biosciences 內部人員 Eduardo Bruno Martins 於 7 月 19 日星期五以每股$3.10 的均價出售了 8,357 股 Sagimet Biosciences 股票。此次交易總價值為$25,906.70。交易完成後，該內部人員在公司擁有 81,213 股股份，價值$251,760.30。該交易已在提交給 SEC 的文件中披露，可通過此超鏈接訪問。此外，董事長 George Kemble 於 7 月 19 日星期五以每股$3.10 的均價出售了 14,062 股 Sagimet Biosciences 股票。這些股票的總價值為$43,592.20。交易完成後，董事長在公司擁有 142,318 股股份，價值約為$441,185.80。此次交易的披露信息可在此處找到。過去一個季度，內部人員已經出售了價值$178,224 的公司股票共 56,958 股。公司內部人員擁有公司股份的 17.60%。</p>
<h2>對 Sagimet Biosciences 的對沖基金看法</h2>
<p>一些對沖基金和其他機構投資者最近對該股票的持倉進行了調整。ORG Partners LLC 在第二季度收購了 Sagimet Biosciences 股票的新頭寸，價值約$43,000。DekaBank Deutsche Girozentrale 在第一季度收購了 Sagimet Biosciences 股票的新頭寸，價值約$113,000。Ikarian Capital LLC 在第一季度收購了 Sagimet Biosciences 股票的新頭寸，價值約$2,236,000。Price T Rowe Associates Inc. MD 在第一季度收購了 Sagimet Biosciences 股票的新頭寸，價值約$91,000。最後，美國國際集團在第一季度增加了其對 Sagimet Biosciences 股票的持股，持股量增加了 312.0%。美國國際集團現在擁有公司股份 11,372 股，價值$62,000，在此期間增加了 8,612 股。公司股份的 87.86% 歸機構投資者和對沖基金所有。</p>
<h2>華爾街分析師預測增長</h2>
<p>許多研究分析師已經發布了關於該公司的報告。高盛集團重申了對 Sagimet Biosciences 的&#34;中性&#34;評級，並在 6 月 28 日星期五的研究報告中發佈了$6.00 的目標股價（之前為$23.00）。JMP 證券重申了對 Sagimet Biosciences 的&#34;市場表現優異&#34;評級，並在 6 月 7 日星期五的研究報告中發佈了$48.00 的目標股價。最後，HC Wainwright 重申了對 Sagimet Biosciences 的&#34;買入&#34;評級，並在 6 月 14 日星期五的研究報告中發佈了$32.00 的目標股價。一位分析師給予該股&#34;持有&#34;評級，而其他六位分析師給予該公司股票&#34;買入&#34;評級。根據 MarketBeat.com 的數據，Sagimet Biosciences 目前的共識評級為&#34;中等買入&#34;，目標股價為$35.80。</p>
<p><strong>閲讀我們關於 SGMT 的最新研究報告</strong></p>
<h2>Sagimet Biosciences 公司簡介（獲取免費報告）</h2>
<p>Sagimet Biosciences Inc 是一家臨牀階段的生物製藥公司，致力於開發稱為脂肪酸合酶（FASN）抑制劑的治療藥物，用於治療因代謝途徑功能失調而導致的疾病。該公司的主力藥物候選者是 Denifanstat，一種每日一次的藥丸和選擇性 FASN 抑制劑，用於治療與代謝功能障礙相關的脂肪肝。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們喜歡的股票，比 Sagimet Biosciences 更好</li>
<li>提供高股息收益的 3 只天然氣股票</li>
<li>為什麼這 2 只股票的認購期權交易量會同時激增</li>
<li>如何投資 FAANG 股票</li>
<li>MarketBeat 周評 - 7/22 - 7/26</li>
<li>投資組合增長的 3 家最佳金融科技股</li>
<li>3M 驚喜和復甦加速：現在加入還不算晚</li>
</ul>
<p><em>這則即時新聞警報是由敍事科技和 MarketBeat 的財務數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前已經經過 MarketBeat 編輯團隊的審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 我對人工智能股票的嚴峻警告（來自 Porter &amp; Company）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzE3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzE3"/></p>
<h2>你現在是否應該投資$1,000 到 Sagimet Biosciences？</h2>
<p>在考慮投資 Sagimet Biosciences 之前，您可能需要聽聽這個消息。</p>
<p>MarketBeat 追蹤華爾街頂尖和表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在應該購買的股票... 而 Sagimet Biosciences 並不在這個名單上。</p>
<p>儘管 Sagimet Biosciences 目前在分析師中有一個 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

SGMT

<p>Sagimet Biosciences Inc.（納斯達克股票代碼：SGMT）在 7 月份看到空頭頭寸下降了 26.8%，賣空 1,670,000 股。目前的空頭頭寸比率為 3.1 天。該公司股票目前交易價格為$3.42，50 天移動平均價格為$4.04。內部人士已經賣出 56,958 股價值$178,224 的公司股票。分析師給予該股票 “中等買入” 評級，目標價格為$35.80</p>

<p>Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) saw a significant drop in short interest in the month of July. As of July 15th, there was short interest totalling 1,670,000 shares, a drop of 26.8% from the June 30th total of 2,280,000 shares. Currently, 8.0% of the shares of the stock are short sold. Based on an average daily volume of 536,900 shares, the short-interest ratio is currently 3.1 days.</p>
<div class="lb-trans"><p>Sagimet Biosciences Inc.（納斯達克股票代碼：SGMT - 獲取免費報告）在 7 月份看到了空頭頭寸顯著下降。截至 7 月 15 日，空頭頭寸總計 1,670,000 股，較 6 月 30 日的 2,280,000 股減少了 26.8%。目前，該股的 8.0% 股份被空頭賣空。基於平均每日交易量為 536,900 股，目前的空頭頭寸比率為 3.1 天。</p>
</div><p>Get <strong>Sagimet Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Sagimet Biosciences</strong> 警報：</p>
</div><h2>Sagimet Biosciences Stock Performance</h2>
<div class="lb-trans"><h2>Sagimet Biosciences 股票表現</h2>
</div><p>Shares of NASDAQ:SGMT traded up $0.02 during midday trading on Friday, hitting $3.42. 239,160 shares of the stock were exchanged, compared to its average volume of 542,058. The business's 50-day moving average price is $4.04 and its 200 day moving average price is $5.52. Sagimet Biosciences has a 12 month low of $2.13 and a 12 month high of $20.71.</p>
<div class="lb-trans"><p>納斯達克股票代碼：SGMT 週五午盤交易中上漲$0.02，達到$3.42。該股交易量為 239,160 股，低於其平均交易量 542,058 股。該公司的 50 天移動平均價格為$4.04，200 天移動平均價格為$5.52。Sagimet Biosciences 過去 12 個月的最低價為$2.13，最高價為$20.71。</p>
</div><p>Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) last released its quarterly earnings results on Wednesday, May 15th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.18. Equities research analysts anticipate that Sagimet Biosciences will post -1.76 earnings per share for the current year.</p>
<div class="lb-trans"><p>Sagimet Biosciences（納斯達克股票代碼：SGMT - 獲取免費報告）上次公佈季度財報是在 5 月 15 日星期三。公司報告該季度每股虧損 ($0.23)，超過了每股 ($0.41) 的共識預期$0.18。股票研究分析師預計，Sagimet Biosciences 今年將實現-1.76 美元的每股盈利。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人員的買賣行為</h2>
</div><p>In related news, Chairman George Kemble sold 14,062 shares of the firm's stock in a transaction on Friday, July 19th. The stock was sold at an average price of $3.10, for a total value of $43,592.20. Following the transaction, the chairman now owns 142,318 shares in the company, valued at $441,185.80. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. In other Sagimet Biosciences news, insider Eduardo Bruno Martins sold 8,357 shares of Sagimet Biosciences stock in a transaction dated Friday, July 19th. The stock was sold at an average price of $3.10, for a total value of $25,906.70. Following the transaction, the insider now owns 81,213 shares in the company, valued at $251,760.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Chairman George Kemble sold 14,062 shares of Sagimet Biosciences stock in a transaction dated Friday, July 19th. The shares were sold at an average price of $3.10, for a total value of $43,592.20. Following the completion of the transaction, the chairman now owns 142,318 shares in the company, valued at approximately $441,185.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 56,958 shares of company stock worth $178,224. Company insiders own 17.60% of the company's stock.</p>
<div class="lb-trans"><p>據相關消息，董事長 George Kemble 於 7 月 19 日星期五以每股$3.10 的均價出售了公司 14,062 股股票。此次交易總價值為$43,592.20。交易完成後，董事長在公司擁有 142,318 股股份，價值$441,185.80。該交易已在提交給證券交易委員會的文件中披露，可通過 SEC 網站訪問。另外，Sagimet Biosciences 內部人員 Eduardo Bruno Martins 於 7 月 19 日星期五以每股$3.10 的均價出售了 8,357 股 Sagimet Biosciences 股票。此次交易總價值為$25,906.70。交易完成後，該內部人員在公司擁有 81,213 股股份，價值$251,760.30。該交易已在提交給 SEC 的文件中披露，可通過此超鏈接訪問。此外，董事長 George Kemble 於 7 月 19 日星期五以每股$3.10 的均價出售了 14,062 股 Sagimet Biosciences 股票。這些股票的總價值為$43,592.20。交易完成後，董事長在公司擁有 142,318 股股份，價值約為$441,185.80。此次交易的披露信息可在此處找到。過去一個季度，內部人員已經出售了價值$178,224 的公司股票共 56,958 股。公司內部人員擁有公司股份的 17.60%。</p>
</div><h2>Hedge Funds Weigh In On Sagimet Biosciences</h2>
<div class="lb-trans"><h2>對 Sagimet Biosciences 的對沖基金看法</h2>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. ORG Partners LLC acquired a new position in shares of Sagimet Biosciences in the second quarter worth approximately $43,000. DekaBank Deutsche Girozentrale acquired a new position in shares of Sagimet Biosciences in the first quarter worth approximately $113,000. Ikarian Capital LLC acquired a new position in shares of Sagimet Biosciences in the first quarter worth approximately $2,236,000. Price T Rowe Associates Inc. MD acquired a new position in shares of Sagimet Biosciences in the first quarter worth approximately $91,000. Finally, American International Group Inc. lifted its stake in shares of Sagimet Biosciences by 312.0% in the first quarter. American International Group Inc. now owns 11,372 shares of the company's stock worth $62,000 after acquiring an additional 8,612 shares during the period. 87.86% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近對該股票的持倉進行了調整。ORG Partners LLC 在第二季度收購了 Sagimet Biosciences 股票的新頭寸，價值約$43,000。DekaBank Deutsche Girozentrale 在第一季度收購了 Sagimet Biosciences 股票的新頭寸，價值約$113,000。Ikarian Capital LLC 在第一季度收購了 Sagimet Biosciences 股票的新頭寸，價值約$2,236,000。Price T Rowe Associates Inc. MD 在第一季度收購了 Sagimet Biosciences 股票的新頭寸，價值約$91,000。最後，美國國際集團在第一季度增加了其對 Sagimet Biosciences 股票的持股，持股量增加了 312.0%。美國國際集團現在擁有公司股份 11,372 股，價值$62,000，在此期間增加了 8,612 股。公司股份的 87.86% 歸機構投資者和對沖基金所有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of research analysts have issued reports on the company. The Goldman Sachs Group reiterated a &#34;neutral&#34; rating and issued a $6.00 target price (down previously from $23.00) on shares of Sagimet Biosciences in a research report on Friday, June 28th. JMP Securities reiterated a &#34;market outperform&#34; rating and issued a $48.00 target price on shares of Sagimet Biosciences in a research report on Friday, June 7th. Finally, HC Wainwright reiterated a &#34;buy&#34; rating and issued a $32.00 target price on shares of Sagimet Biosciences in a research report on Friday, June 14th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, Sagimet Biosciences presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $35.80.</p>
<div class="lb-trans"><p>許多研究分析師已經發布了關於該公司的報告。高盛集團重申了對 Sagimet Biosciences 的&#34;中性&#34;評級，並在 6 月 28 日星期五的研究報告中發佈了$6.00 的目標股價（之前為$23.00）。JMP 證券重申了對 Sagimet Biosciences 的&#34;市場表現優異&#34;評級，並在 6 月 7 日星期五的研究報告中發佈了$48.00 的目標股價。最後，HC Wainwright 重申了對 Sagimet Biosciences 的&#34;買入&#34;評級，並在 6 月 14 日星期五的研究報告中發佈了$32.00 的目標股價。一位分析師給予該股&#34;持有&#34;評級，而其他六位分析師給予該公司股票&#34;買入&#34;評級。根據 MarketBeat.com 的數據，Sagimet Biosciences 目前的共識評級為&#34;中等買入&#34;，目標股價為$35.80。</p>
</div><p><strong>Read Our Latest Research Report on SGMT</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 SGMT 的最新研究報告</strong></p>
</div><h2>Sagimet Biosciences Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>Sagimet Biosciences 公司簡介（獲取免費報告）</h2>
</div><p>Sagimet Biosciences Inc, a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis.</p>
<div class="lb-trans"><p>Sagimet Biosciences Inc 是一家臨牀階段的生物製藥公司，致力於開發稱為脂肪酸合酶（FASN）抑制劑的治療藥物，用於治療因代謝途徑功能失調而導致的疾病。該公司的主力藥物候選者是 Denifanstat，一種每日一次的藥丸和選擇性 FASN 抑制劑，用於治療與代謝功能障礙相關的脂肪肝。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Sagimet Biosciences</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>Why Call Options Volume for These 2 Stocks Spiked Together</li>
<li>How to Invest in the FAANG Stocks</li>
<li>MarketBeat Week in Review – 7/22 - 7/26</li>
<li>3 Best Fintech Stocks for a Portfolio Boost</li>
<li>3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In</li>
</ul>
<div class="lb-trans"><h2>精選文章</h2>
<ul>
<li>五隻我們喜歡的股票，比 Sagimet Biosciences 更好</li>
<li>提供高股息收益的 3 只天然氣股票</li>
<li>為什麼這 2 只股票的認購期權交易量會同時激增</li>
<li>如何投資 FAANG 股票</li>
<li>MarketBeat 周評 - 7/22 - 7/26</li>
<li>投資組合增長的 3 家最佳金融科技股</li>
<li>3M 驚喜和復甦加速：現在加入還不算晚</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由敍事科技和 MarketBeat 的財務數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前已經經過 MarketBeat 編輯團隊的審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ My grim warning about AI stocks (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 我對人工智能股票的嚴峻警告（來自 Porter &amp; Company）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzE3" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8717&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Sagimet Biosciences right now?</h2>
<div class="lb-trans"><h2>你現在是否應該投資$1,000 到 Sagimet Biosciences？</h2>
</div><p>Before you consider Sagimet Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Sagimet Biosciences 之前，您可能需要聽聽這個消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sagimet Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街頂尖和表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在應該購買的股票... 而 Sagimet Biosciences 並不在這個名單上。</p>
</div><p>While Sagimet Biosciences currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 Sagimet Biosciences 目前在分析師中有一個 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Sagimet Biosciences Inc.（納斯達克股票代碼：SGMT）7 月份的空頭頭寸下降了 26.8%